company background image
ONCO

Oncopeptides OM:ONCO Stock Report

Last Price

kr45.70

Market Cap

kr4.1b

7D

7.5%

1Y

20.5%

Updated

13 Aug, 2022

Data

Company Financials +
ONCO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ONCO Stock Overview

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally.

Oncopeptides Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncopeptides
Historical stock prices
Current Share Pricekr45.70
52 Week Highkr54.70
52 Week Lowkr3.40
Beta-1.59
1 Month Change58.02%
3 Month Change444.05%
1 Year Change20.52%
3 Year Change-67.45%
5 Year Change-18.76%
Change since IPO6.28%

Recent News & Updates

Shareholder Returns

ONCOSE BiotechsSE Market
7D7.5%1.6%2.3%
1Y20.5%-20.6%-21.8%

Return vs Industry: ONCO exceeded the Swedish Biotechs industry which returned -20.6% over the past year.

Return vs Market: ONCO exceeded the Swedish Market which returned -21.8% over the past year.

Price Volatility

Is ONCO's price volatile compared to industry and market?
ONCO volatility
ONCO Average Weekly Movement23.9%
Biotechs Industry Average Movement8.9%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market4.5%

Stable Share Price: ONCO is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 24% a week.

Volatility Over Time: ONCO's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
200076Jakob Lindberghttps://www.oncopeptides.com/sv

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Oncopeptides Fundamentals Summary

How do Oncopeptides's earnings and revenue compare to its market cap?
ONCO fundamental statistics
Market Capkr4.13b
Earnings (TTM)-kr1.33b
Revenue (TTM)kr41.32m

100.0x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ONCO income statement (TTM)
Revenuekr41.32m
Cost of Revenuekr40.99m
Gross Profitkr332.00k
Other Expenseskr1.33b
Earnings-kr1.33b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 09, 2022

Earnings per share (EPS)-14.72
Gross Margin0.80%
Net Profit Margin-3,218.74%
Debt/Equity Ratio0.0%

How did ONCO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ONCO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONCO?

Other financial metrics that can be useful for relative valuation.

ONCO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue97.8x
Enterprise Value/EBITDA-2.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does ONCO's PB Ratio compare to its peers?

ONCO PB Ratio vs Peers
The above table shows the PB ratio for ONCO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average10.3x
HNSA Hansa Biopharma
7.6x43.0%kr3.7b
XBRANE Xbrane Biopharma
6x181.6%kr2.2b
BONEX Bonesupport Holding
20.5x120.2%kr4.9b
HAMLET B Hamlet Pharma
11xn/akr445.4m
ONCO Oncopeptides
70.8x29.7%kr4.1b

Price-To-Book vs Peers: ONCO is expensive based on its Price-To-Book Ratio (70.8x) compared to the peer average (10.3x).


Price to Earnings Ratio vs Industry

How does ONCO's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Book vs Industry: ONCO is expensive based on its Price-To-Book Ratio (70.8x) compared to the Swedish Biotechs industry average (2.4x)


Price to Book Ratio vs Fair Ratio

What is ONCO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONCO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio70.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ONCO's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ONCO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ONCO (SEK45.7) is trading below our estimate of fair value (SEK345.01)

Significantly Below Fair Value: ONCO is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Future Growth

How is Oncopeptides forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


29.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ONCO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).

Earnings vs Market: ONCO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ONCO is expected to become profitable in the next 3 years.

Revenue vs Market: ONCO's revenue is expected to decline over the next 3 years (-19.3% per year).

High Growth Revenue: ONCO's revenue is forecast to decline over the next 3 years (-19.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ONCO's Return on Equity is forecast to be low in 3 years time (5.1%).


Discover growth companies

Past Performance

How has Oncopeptides performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-36.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ONCO is currently unprofitable.

Growing Profit Margin: ONCO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ONCO is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.

Accelerating Growth: Unable to compare ONCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.1%).


Return on Equity

High ROE: ONCO has a negative Return on Equity (-2279.89%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Oncopeptides's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ONCO's short term assets (SEK122.5M) exceed its short term liabilities (SEK84.3M).

Long Term Liabilities: ONCO's short term assets (SEK122.5M) exceed its long term liabilities (SEK6.5M).


Debt to Equity History and Analysis

Debt Level: ONCO is debt free.

Reducing Debt: ONCO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONCO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ONCO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.8% each year


Discover healthy companies

Dividend

What is Oncopeptides's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ONCO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ONCO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ONCO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONCO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ONCO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Jakob Lindberg (50 yo)

0.75

Tenure

kr992,000

Compensation

Dr. Jakob Lindberg, Med. Lic serves as Chief Executive Officer at Oncopeptides AB (publ) since November 15, 2021. He serves as an Independent Director at Camurus AB (publ) since May 06, 2021. He had been C...


CEO Compensation Analysis

Compensation vs Market: Jakob's total compensation ($USD97.19K) is below average for companies of similar size in the Swedish market ($USD548.11K).

Compensation vs Earnings: Jakob's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ONCO's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: ONCO's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.


Top Shareholders

Company Information

Oncopeptides AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Oncopeptides AB (publ)
  • Ticker: ONCO
  • Exchange: OM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr4.130b
  • Shares outstanding: 90.37m
  • Website: https://www.oncopeptides.com/sv

Number of Employees


Location

  • Oncopeptides AB (publ)
  • Vastra Tradgardsgatan 15
  • Stockholm
  • Stockholm County
  • 111 53
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/13 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.